Aptevo Therapeutics (APVO) Net Cash Flow (2015 - 2026)
Aptevo Therapeutics (APVO) posted Net Cash Flow of -$7.1 million for Q1 2026, down 1396.18% sequentially from $550000.0 in Q4 2025, and down 8.43% YoY from -$7.8 million in Q1 2025.
Aptevo Therapeutics (APVO) Net Cash Flow (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Net Cash Flow for 12 years, with the latest figure at -$7.1 million in Q1 2026.
- Quarterly Net Cash Flow fell 8.43% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.7 million (up 565.18% YoY) and the FY2025 annual result came in at $12.9 million, up 257.47% from the prior year.
- Net Cash Flow retreated to -$7.1 million in Q1 2026 per APVO's latest filing, from $550000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $37.0 million in Q3 2025 and troughed at -$10.1 million in Q1 2022.
- A 5-year average of -$375176.5 and a median of -$2.2 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow plunged 3789.83% in 2023, then soared 11784.23% in 2025.
- Over 5 years, Net Cash Flow stood at $59000.0 in 2022, then slumped by 3789.83% to -$2.2 million in 2023, then soared by 144.14% to $961000.0 in 2024, then slumped by 42.77% to $550000.0 in 2025, then sank by 1396.18% to -$7.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$7.1 million, $550000.0, and $37.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Aptevo Therapeutics | 3.17 Mn | -6.63 Mn | - | -4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.69 Mn |
| Jun 30, 2026 | -4.69 Mn |
| Mar 31, 2026 | -7.13 Mn |
| Mar 31, 2026 | -7.13 Mn |
| Dec 31, 2025 | 550,000.00 |
| Dec 31, 2025 | 550,000.00 |
| Sep 30, 2025 | 37.04 Mn |
| Sep 30, 2025 | 37.04 Mn |
| Jun 30, 2025 | 7.27 Mn |
| Jun 30, 2025 | 7.27 Mn |
| Mar 31, 2025 | -6.58 Mn |
| Mar 31, 2025 | -6.58 Mn |
| Dec 31, 2024 | 961,000.00 |
| Dec 31, 2024 | 961,000.00 |
| Sep 30, 2024 | -317,000.00 |
| Sep 30, 2024 | -317,000.00 |
| Jun 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | -2.18 Mn |
| Mar 31, 2024 | -6.65 Mn |
| Mar 31, 2024 | -6.65 Mn |